← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Revidia Therapeutics, Inc
Ellsworth, ME
$2,857,482
Total funding
2
Grants
Funding over time
peak $1.4M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,857,482 · 2
By mechanism
R44$2,857,482 · 2
Investigators at Revidia Therapeutics, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients$1,358,179
R44 · FY2024 · HL
Development of the PTP1B inhibitor MSI-1436 for therapeutic stimulation of heart regeneration following acute myocardial infarction$769,681
R44 · FY2017 · HL
Development of the PTP1B inhibitor MSI-1436 for therapeutic stimulation of heart regeneration following acute myocardial infarction$729,622
R44 · FY2018 · HL